In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: Modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models
Ivana Stojanović(University of Belgrade), Mogens H. Claësson(University of Copenhagen), Emanuela Mazzon(Centro Neurolesi Bonino Pulejo), Djordje Miljković(University of Belgrade), Stanislava Stošić‐Grujičić(Institute for Biological Research “Siniša Stanković”), Salvatore Cuzzocrea(University of Messina), Joseph Kim(University of Wisconsin–Madison), Mingjun Wang(Houston Methodist), Ferdinando Nicoletti(University of Catania), Marco Donia(University of Copenhagen), Yousef Al Abed(IJ Research (United States)), Katia Mangano(University of Catania)
Cited by 59
Related Papers
Natural products in drug discovery: advances and opportunities
|Nature Reviews Drug Discovery|2021|5.2k
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
|Oncotarget|2011|579
GSK-3 as potential target for therapeutic intervention in cancer
|Oncotarget|2014|508
The neuropathic pain: An overview of the current treatment and future therapeutic approaches
|International Journal of Immunopathology and Pharmacology|2019|495